2017 International League Against Epilepsy classifications of seizures and epilepsy are steps in the right direction

TY - JOUR

T1 - 2017 International League Against Epilepsy classifications of seizures and epilepsy are steps in the right direction

AU - Fisher, Robert S.

AU - Cross, Helen

AU - D'Souza, Carol

AU - French, Jacqueline A.

AU - Haut, Sheryl

AU - Higurashi, Norimichi

AU - Hirsch, Edouard

AU - Jansen, Floor E.

AU - Peltola, Jukka

AU - Moshé, Solomon L.

AU - Perucca, Emilio

AU - Lagae, Lieven

AU - Roulet-Perez, Eliane

AU - Schulze-Bonhage, Andreas

AU - Scheffer, Ingrid E.

AU - Somerville, Ernest

AU - Sperling, Michael R.

AU - Wiebe, Samuel

AU - Yacubian, Elza Márcia

AU - Zuberi, Sameer

N1 - Funding Information: R.S.F. holds stock or options in Zeto, Cerebral Therapeutics, Avails Medical, and Smart‐Monitor and consults for Medtronic. J.F. has received New York University (NYU) salary support from the Epilepsy Foundation; has received compensation for consulting work and/or attending scientific advisory boards on behalf of the Epilepsy Study Consortium for Acadia, Adamas, Addex, Aeonian, Anavex, Axcella Health, Axovant, Biogen, BioMotiv/Koutif, Blackfynn, Bloom Science, BridgeValley, Cavion, Cerebral Therapeutics, Cerevel, Crossject, CuroNZ, Eisai, Empatica, Engage Therapeutics, Epitel, GW Pharma, Idorsia, Impax, Ionis, J&J Pharmaceuticals, Marinus, Neurelis, Novartis, Otsuka Pharmaceutical Development, Ovid Therapeutics, Pfizer, Pfizer‐Neusentis, Praxis, Redpin Therapeutics, Sage, Sancillio, Shire, SK Life Sciences, Springworks, Stoke, Sunovion, Supernus, Takeda, UCB, Ultragenyx, Vyera, West Therapeutic Development, Xenon Pharmaceuticals, Xeris, Zogenix, and Zynerba; has received research grants from Biogen, Cavion, Eisai, Engage, GW Pharma, Lundbeck, Neurelis, Ovid, SK Life Sciences, Sunovion, UCB, Zogenix, the Epilepsy Research Foundation, the Epilepsy Study Consortium, and the National Institute of Neurological Disorders and Stroke; is on the editorial boards of Lancet Neurology and Neurology Today; is scientific officer for the Epilepsy Foundation, for which NYU receives salary support; and has received travel reimbursement related to research, advisory meetings, or presentation of results at scientific meetings from the Epilepsy Study Consortium, the Epilepsy Foundation, Adamas, Axovant, Biogen, Blackfynn, Crossject, CuroNz, Engage, Idorsia, Neurelis, Novartis, Otsuka, Ovid, Pfizer, Redpin, Sage, SK Life Science, Takeda, and UCB. L.L. has received speaker honoraria from and is participating on advisory boards for Zogenix, Livanova, UCB, Eisai, Novartis, NEL, and Epihunter. S.L.M. is the Charles Frost Chair in Neurosurgery and Neurology; is partially funded by grants from the National Institutes of Health (U54 NS100064 and NS43209), US Department of Defense (W81XWH‐13‐1‐0180), Heffer Family and Segal Family Foundations, and Abbe Goldstein/Joshua Lurie and Laurie Marsh/Dan Levitz families; is serving as Associate Editor of Neurobiology of Disease; is on the editorial boards of Brain and Development, Pediatric Neurology, and Physiological Research; receives from Elsevier an annual compensation for his work as Associate Editor of Neurobiology of Disease and royalties from two books he coedited; has received consultancy fees from Mallinckrodt and UCB; and has no conflicts of interest in regard to this article. J.P. has participated in clinical trials for Eisai, UCB, and Bial; has received research grants from Eisai, Medtronic, UCB, and Cyberonics; has received speaker honoraria from Cyberonics, Eisai, Medtronic, Orion Pharma, and UCB; has received support for travel congresses from Cyberonics, Eisai, Medtronic, and UCB; and has participated on advisory boards for Cyberonics, Eisai, Medtronic, UCB, and Pfizer. E.P. has received speaker and/consultancy fees from Biogen, Eisai, GW Pharma, Sanofi, Takeda, and UCB. I.E.S. has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline, BioMarin, Nutricia, and Xenon Pharmaceuticals; has served on editorial boards for Annals of Neurology, Neurology, and Epileptic Disorders; may accrue future revenue on pending patent WO61/010176 (filed: 2008; Therapeutic Compound); has received speaker honoraria from GlaxoSmithKline, Athena Diagnostics, UCB, BioMarin, and Eisai; has received funding for travel from Athena Diagnostics, UCB, Biocodex, GlaxoSmithKline, Biomarin, and Eisai; and has received research support from the National Health and Medical Research Council of Australia, National Institutes of Health, Australian Research Council, Health Research Council of New Zealand, CURE, and March of Dimes. E.S. has no disclosures relevant to this publication but has performed clinical trials for, consulted to, received speaker fees from, and/or received travel support from Eisai, UCB Pharma, Zynerba, SK Life Sciences, Sci‐Gen, Marinus, Upsher‐Smith, Bial, Novartis, the Epilepsy Study Consortium, the New South Wales Ombudsman, and the National Transport Commission of Australia. M.R.S. has consulted for Medtronic, Eisai, and NeurologyLive and has research contracts with SK Life Science, UCB Pharma, Eisai, Neurelis, Medtronic, Takeda, Cavion, and Engage. S.M.W. has received unrestricted educational grants from UCB Pharma and Eisai. E.M.Y. has received speaker fees from Abbott and UCB. None of the other authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

PY - 2019/6

Y1 - 2019/6

UR - https://www.scopus.com/pages/publications/85065716838

UR - https://www.scopus.com/pages/publications/85065716838#tab=citedBy

U2 - 10.1111/epi.15052

DO - 10.1111/epi.15052

M3 - Comment/debate

C2 - 31074833

AN - SCOPUS:85065716838

SN - 0013-9580

VL - 60

SP - 1040

EP - 1044

JO - Epilepsia

JF - Epilepsia

IS - 6

ER -